Do Peptides Cause Cancer? The IGF-1 & Angiogenesis Question

"Do peptides cause cancer?" is one of the most common safety questions about the gray-market peptide world — and it deserves a careful, honest answer. No human study has demonstrated that therapeutic peptides such as BPC-157, ipamorelin, sermorelin, or CJC-1295 cause cancer. But that reassuring statement carries an important second half: no long-term human safety data exists for most of these compounds^[6][7], so the honest answer is not "safe" — it is "unknown, with two theoretically coherent concerns worth understanding." This article maps those concerns precisely, explains what the evidence actually shows, and gives people with cancer history the specific guidance they need. See our peptide directory for compound-level guides.

The two theoretical cancer concerns — and why they are not equivalent to evidence

When researchers ask whether a drug or supplement might raise cancer risk, they look for three things: a plausible biological mechanism, epidemiologic associations in humans, and ideally controlled evidence that exposure leads to disease. For therapeutic peptides, the picture is uneven: there are plausible mechanisms, partial epidemiologic signals in related situations (not peptide use itself), and essentially no controlled human evidence either way. Understanding what type of evidence we have — and what we do not — is the whole exercise.

Concern #1 — GH-secretagogue peptides raise IGF-1, and IGF-1 is epidemiologically linked to some cancers

Growth-hormone-releasing peptides (GHRPs) — including ipamorelin, GHRP-2, GHRP-6 — and growth-hormone-releasing hormone analogs (sermorelin, CJC-1295, tesamorelin) work by stimulating the pituitary to release more growth hormone. That GH pulse then triggers the liver to produce insulin-like growth factor 1 (IGF-1), the downstream mediator of most of GH's anabolic effects. This is the intended mechanism — but IGF-1 does not only build muscle and promote recovery.

A landmark 2004 systematic review and meta-regression published in The Lancet analyzed 21 prospective studies and found that higher circulating IGF-I was associated with increased risk of prostate cancer, premenopausal breast cancer, and colorectal cancer^[1]. The associations were statistically significant and have been replicated in subsequent work. This is real epidemiology — but it is also epidemiology of naturally varying IGF-1 levels across populations, not a study of people using peptide injections. The Renehan analysis does not establish that raising IGF-1 from normal to high-normal via a GH-secretagogue peptide is harmful.

The strongest human analog to "what happens to cancer risk when IGF-1 is pathologically elevated for years" is acromegaly — a condition where a pituitary tumor overproduces GH and drives IGF-1 far above the normal range chronically. A 2025 systematic review and meta-analysis found that patients with acromegaly have a statistically elevated breast cancer risk^[2]. But acromegaly involves GH and IGF-1 levels many times above the physiologic range, sustained for years, caused by autonomous tumor secretion — not the modest pulsatile stimulation that a GH-secretagogue peptide produces in a user with intact pituitary feedback.

The closest direct evidence comes from long-term GH replacement therapy in adults with documented GH deficiency. A 2022 analysis of 15,809 GH-treated adults across multiple national registries found no markedly elevated cancer incidence compared to the general population^[3]. However, this cohort was GH-deficient — replacement brought their IGF-1 into the normal range, not above it. People using GH-secretagogue peptides without documented GH deficiency are a different population: they may already have normal IGF-1 and are pushing it higher, which is precisely the scenario the cancer epidemiology flags. That specific scenario has not been studied.

Concern #2 — BPC-157 promotes angiogenesis via VEGFR2, which could theoretically feed tumors

BPC-157's proposed mechanism of action in tissue healing is intimately tied to angiogenesis — the growth of new blood vessels. A 2017 animal study in the Journal of Molecular Medicine demonstrated that BPC-157's pro-angiogenic effects are mediated via VEGFR2 (vascular endothelial growth factor receptor 2) activation and up-regulation of downstream effectors^[4]. The 2025 Sikiric review further characterizes BPC-157 as modulating the VEGF/angiogenesis system as part of its pleotropic effects^[5]. Angiogenesis is exactly what allows wounds to heal and new tissue to form — but it is also exactly what established tumors exploit to grow their own blood supply and spread.

An entire class of cancer drugs — anti-angiogenic agents such as bevacizumab (Avastin), sunitinib, and sorafenib — were developed specifically to block VEGFR2 and related pathways in order to starve tumors of new blood vessels. A compound that activates the same pathway is, by that logic, doing the opposite of what oncologists do pharmacologically to fight tumor growth. This does not mean BPC-157 causes cancer in healthy tissue. Angiogenesis is a normal physiologic process; most cells are not pre-cancerous. But for a person with an existing tumor, or micrometastatic disease not yet clinically apparent, the concern is coherent: BPC-157 might provide angiogenic support to tumor cells the same way it provides it to injured tissue. This has never been tested in humans.

What the evidence actually shows

Let us be precise about what "no human evidence of cancer causation" means. The three uncontrolled human pilot studies of BPC-157 collectively involved fewer than 30 subjects and were not designed to assess long-term safety^[6]. No adverse effects, including cancer, were reported in those pilots^[7] — but a ~30-person, short-duration study cannot detect cancers that may take years to develop or that affect a small fraction of users. For GH-secretagogue peptides, there are essentially no published clinical studies in healthy adults; virtually all human GH data comes from either GH-deficient patients receiving replacement, or acromegalic patients with pathologic overproduction.

The absence of human evidence cuts both ways. There is no evidence of cancer causation — and no adequate evidence that rules it out. This is not semantic gymnastics; it is the actual state of the science. The theoretical concerns are not dismissed by absence of evidence when the studies required to address them have never been done.

The bigger real issue — long-term human safety data does not exist

A 2026 pharmaceutical development review of BPC-157 identified the fundamental barrier to clinical translation: not the absence of biological activity in animals, but the absence of fundamental human pharmaceutical science — characterized formulations, validated pharmacokinetics, completed Phase II safety trials^[6]. The review found zero completed Phase II trials for BPC-157. A similar vacuum exists for most gray-market GH-secretagogue peptides: ipamorelin, GHRP-2, GHRP-6, and CJC-1295 have no published Phase II or III human trials assessing safety in healthy adults. The FDA requires thousands of participants and years of follow-up to characterize a drug's safety profile with statistical confidence. These compounds have not entered that process.

McGuire et al.'s 2025 narrative review reaches a direct conclusion: BPC-157 "should be considered investigational, and its use approached with caution"^[7]. This framing applies equally to GH-secretagogue peptides used in healthy, non-deficient individuals. The absence of a cancer signal in the available data reflects the inadequacy of the data, not a clean safety bill.

Frequently asked questions